Stocks · News reference

8-K filing — Arcturus Therapeutics Holdings Inc. (ARCT)

Aug 25, 2026, 10:00 AMSEC EDGAR

Filed: 2026-08-25 AccNo: 0001193805-26-001130 Size: 589 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Globenewswire IncAug 26, 2026, 1:46 PMResearchandmarkets.Com
mRNA Therapeutics Market Outlook Report 2026-2035 Featuring Profiles of Arcturus Therapeutics, BioNTech, CureVac, Moderna, Providence Therapeutics, RNAimmune, Recode Therapeutics, and More
The global mRNA therapeutics market (excluding COVID-19 applications) is projected to grow from USD 201 million in 2026 to USD 9.98 billion by 2035, with a 63% CAGR. Growth is driven by expanding oncology and rare disease pipelines, advances in lipid nanoparticle delivery, and strategic partnerships. However, challenges include tissue-selective delivery limitations, repeat-dose tolerability concerns, and regulatory complexities. Moderna and BioNTech dominate with approximately 70% of pipeline activity.
Read original at globenewswire-inc
MRNA BNTX ARCT
BenzingaAug 25, 2026, 4:24 PMBenzinga Newsdesk
Arcturus Therapeutics shares are trading higher. The company announced it will present data on ARCT-810 mRNA therapy in Ornithine Transcarbamylase Deficiency at the 2026 SSIEM Annual Symposium.
Read original at benzinga
ARCT
BenzingaAug 20, 2026, 3:18 AMRadhika Anilkumar Nadig
Elon Musk Says mRNA Has ‘Tremendous’ Potential After Moderna, Merck Cancer Vaccine Breakthrough — MRNA Stock Falls Over 11% in Premarket (UPDATED)
Elon Musk said mRNA could fundamentally change disease treatment, turning medicine into a software problem.
Read original at benzinga
ARCT MRK MRNA TMO